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Reparative response by bone marrow (BM)-derived pro-
genitor cells (PCs) to ischemia is a multistep process 
that comprises the detachment from the BM endosteal 
niche through activation of osteoclasts and proteolytic 
enzymes (such as matrix metalloproteinases (MMPs)), 
mobilization to the circulation, and homing to the 
injured tissue. We previously showed that intramyocar-
dial nerve growth factor gene transfer (NGF-GT) pro-
motes cardiac repair following myocardial infarction 
(MI) in mice. Here, we investigate the impact of cardiac 
NGF-GT on postinfarction BM-derived PCs mobilization 
and homing at different time points after adenovirus-
mediated NGF-GT in mice. Immunohistochemistry and 
flow cytometry newly illustrate the temporal profile of 
osteoclast and activation of MMP9, PCs expansion in the 
BM, and liberation/homing to the injured myocardium. 
NGF-GT amplified these responses and increased the BM 
levels of active osteoclasts and MMP9, which were not 
observed in MMP9-deficient mice. Taken together, our 
results suggest a novel role for NGF in BM-derived PCs 
mobilization/homing following MI.
Received 26 February 2015; accepted 12 August 2015; advance online  
publication 6 October 2015. doi:10.1038/mt.2015.167
INTRODUCTION
The bone marrow (BM) contains different types of progenitor cells 
(PCs), which are distributed in the osteoblastic (also known as 
endosteal) and the vascular niches.1,2 In physiologic conditions, 
a relatively small number of stem/PCs are released from the BM 
into the circulation, together with mature hematopoietic cells.3 
While the latter ensure the regular turnover of circulating leuko-
cytes, erythrocytes, and platelets, the former are supposed to par-
ticipate in maintaining the integrity of the peripheral vasculature. 
The homeostatic control of mobilization involves retaining and 
releasing mechanisms within the BM and modulatory influences 
from the extra-BM environment. Following an acute ischemic 
event, such as myocardial infarction (MI), this homeostasis is dis-
rupted leading to an abundant release of immature and maturing 
hematopoietic cells into the circulation, followed by homing to 
the ischemic tissue.4,5 The short-term availability of immature cells 
to peripheral organs is thought to be a specialized host defense 
response, contributing to postischemic healing through stimula-
tion of vascularization of the injured tissue. Recent reports have 
shown that mobilization of vascular PCs from the BM requires 
many complex signals that concur in detaching the PCs from the 
stroma. Some cytokines (including the c-kit ligand stem cell fac-
tor (SCF),6 the granulocyte colony–stimulating factor (G-CSF),7 
stromal cell–derived factor-1 (SDF-1),8,9 and angiogenic fac-
tors such as vascular endothelial growth factor A9,10) have been 
shown to activate the release of proteolytic enzymes, including 
matrix metalloproteinases (MMPs) and cathepsins, which cleave 
the membrane-bound c-kit ligand, SCF, and other components 
of the extracellular matrix that normally support the adhe-
sion of stem cells to the niche.3,11,12 Osteoclasts are a rich source 
of MMPs, cathepsins, and other mobilizing cytokines, such as 
interleukin-8.13,14
Nerve growth factor (NGF) is a secreted glycoprotein with 
proangiogenic and antiapoptotic properties.15–17 Previous data 
from our laboratory indicate that: (i) NGF expression is increased 
in the heart of human subjects who died early after a MI, (ii) local 
adenovirus (Ad)-mediated NGF gene transfer (GT) promotes 
post-MI vascular regeneration and myocardial protection result-
ing in increased post-MI survival and improved cardiac function 
in mice, and (iii) cardiac Ad-mediated NGF overexpression is 
associated with the expansion of Lineage negative (Linneg)/c-kitpos 
PCs in the mouse left ventricle (LV).15 Following the latter find-
ings, we aimed to investigate whether therapeutically induced 
increases in cardiac NGF levels stimulates the mobilization of PCs 
from the BM and their homing to the infarcted heart, thus con-
tributing to myocardial healing. This study has characterized, for 
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Figure 1 Effects of NGF on osteoclast activation. (a) Mouse femurs and tibiae were collected at 1, 2, 3, and 6 days after surgery. Bar graph shows the 
kinetics of osteoclast activation up to 6 days postsurgery and cardiac gene transfer (GT). Data are expressed as number of TRAPpos osteoclasts/cm of end-
osteal bone. (b) Representative microphotographs of TRAPpos osteoclasts (in purple and pointed by arrows) at 1 day after surgery and GT. Bar = 100 µm. 
Bar graphs show the presence of hNGF restricted to the (c) bone marrow (BM) supernatant and (d) peripheral blood plasma of mice that received cardiac 
Ad.hNGF-GT. Analyses were performed at 1 and 3 days postsurgery and GT (n = 3–4/group). (e) ELISA for endogenous NGF in the mouse peripheral 
blood plasma at 3 days postsurgery (n = 6/group). (f) Representative microphotograph showing the presence of NGF high-affinity receptor TrkA (green 
fluorescence) in terminally differentiated multinucleated osteoclasts (pointed by arrows). Nuclei are stained by 4′,6-diamidino-2-phenylindole (blue fluo-
rescence). Bar = 20 µm. (g) Bar graphs show the effect of NGF on TRAP expression in murine BM-derived mononuclear cells (MNCs) undergoing osteoclast 
differentiation. Data are expressed as percentage of TRAPpos osteoclasts/total cells. (h) Representative microphotographs of TRAPpos cells (in red and pointed 
by arrows) at 6 days after treatment with NGF. Bar = 100 µm. Data are expressed as mean ± SEM. *P < 0.05 and **P < 0.01 versus sham/Ad.Null; †P < 0.05 
and ††P < 0.01 versus MI/Ad.Null; ‡P < 0.05 versus no NGF (n = 5 samples/group for TRAP staining on mouse bones and 3 samples/group for TRAP staining 
on isolated mouse MNCs). Ad, adenovirus; hNGF, human nerve growth factor; MI, myocardial infarction; N.D., not detectable; TRAP, tartrate-resistant 
acid phosphatase.
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the first time, the time-course of osteoclasts activation and BM 
c-kitpos cell expansion in response to MI. Moreover, we provide 
novel evidence supporting the hypothesis that after Ad-mediated 
intracardiac delivery of human NGF, the transgenic NGF reaches 
the BM, where it activates osteoclasts that in turn trigger MMP9 
activation and SCF release. These pathways lead to increased 
c-kitpos cells egress from the BM and their homing to the infarcted 
heart and are associated with improved myocardial blood flow 
and cardiac function in mice receiving NGF-GT.
RESULTS
NGF induces osteoclast activation and increases 
MMP9-positive cells in the BM
Osteoclasts typically reside in endosteal pits and derive from the 
fusion of monocytes through a reaction that is triggered by recep-
tor activator of NF-κB ligand (RANKL) and macrophage colony–
stimulating factor (M-CSF) and involves the transcription factor 
NF-κB.18 Firstly, we investigated the effect of MI and concomi-
tant NGF cardiac overexpression on osteoclast activation. For this 
purpose, a mouse model of MI induced by permanent ligation of 
the left anterior descending coronary artery15,19 was employed. 
Following MI induction, mice received intracardiac injections 
of either Ad.hNGF or an empty vector (Ad.Null, used as control 
of NGF-GT as well as to characterize the BM response to MI in 
the absence of a gene therapy intervention). Sham-operated mice 
receiving Ad.Null served for reference. At 1, 2, 3, and 6 days after 
the intervention, the abundance of acid phosphatase-rich osteo-
clasts in the femurs and tibias was assessed by immunohistochem-
istry for tartrate-resistant acid phosphatase (TRAP). As shown in 
Figure 1, in Ad.Null-given mice, the number of TRAPpos active 
osteoclasts lining the endosteal surface was increased at 3 days 
post-MI compared to sham operation. This change was tran-
sient (not observable at 6 days), thus suggesting that osteoclast 
activation is not sustained by MI alone. Of note, assessment of 
TRAPpos osteoclasts in bones collected from MI or sham-operated 
mice receiving phosphate-buffered saline showed similar results, 
thus excluding the possibility of an Ad-mediated effect on osteo-
clast activation (data not shown). Remarkably, intramyocardial 
Ad.hNGF increased the number of TRAPpos osteoclasts already at 
1 and 2 days post-MI, thus accelerating osteoclast activation in 
comparison to the Ad.Null group (Figure 1a,b). Moreover, after 
NGF-GT, osteoclast activation was sustained up to the last time 
point (6 days post-MI) of this protocol (Figure 1a). In order to 
verify if the transgenic human protein reaches the BM through 
the circulation, we employed an enzyme-linked immunosorbent 
assay (ELISA) selective for hNGF. Human NGF was measured in 
the peripheral blood (PB)-derived plasma and BM supernatants 
at 1 and 3 days post-GT in MI mice. In mice receiving NGF-GT, 
hNGF was present in both plasma and BM, whereas hNGF could 
not be detected in Ad.Null-given mice (Figure 1c,d, respectively). 
In addition, the levels of endogenous (mouse) NGF also increased 
in the plasma of infarcted mice, but no further increase was 
observed after hNGF-GT (Figure 1e).
Next, to determine if osteoclasts could be a cellular target for 
hNGF, the expression of the NGF high-affinity receptor TrkA 
on osteoclasts derived from in vitro differentiation of mouse 
BM-derived mononuclear cells (BM-MNCs) was assessed by 
immunocytochemistry. As shown in Figure 1f, terminally dif-
ferentiated multinucleated osteoclasts (which have a larger size in 
comparisons to their MNC precursors) stained positive for TrkA. 
Moreover, using an in vitro osteoclast differentiation assay, we found 
that hNGF potentiates the effect of M-CSF and RANKL, which are 
the natural activators of osteoclast  formation20  (Figure 1g,h).
Osteoclasts are a rich source of proteolytic enzymes, which 
facilitate the detachment of stem/PCs from the extracellular 
matrix.14 We found that, although MI alone does not affect the BM 
level of active MMP9, hNGF gene therapy increases the number 
of cells expressing the active form of MMP9 lining the trabecular 
bone of infarcted mice up to 6 days (Figure 2a,b). In contrast, 
although MI increased the number of MMP2pos cells, no differ-
ence was observed after NGF treatment (Figure 3a,b).
MMP9 is involved in stem/PC mobilization by shedding the 
membrane-bound cytokine SCF within the BM and releasing this 
cytokine into the circulation.6 Therefore, we next sought to eval-
uate the effect of hNGF overexpression on SCF levels in the BM 
Figure 2 NGF-dependent increase of MMP9 in the mouse bone 
marrow (BM) after MI and gene transfer (GT). (a) Bar graph shows 
the expression of MMP9 in the mouse BM parenchyma up to 6 days 
postsurgery and cardiac GT. Data are expressed as number of MMP9pos 
cells/mm2 of BM parenchyma. (b) Representative microphotographs of 
MMP9pos BM cells (in brown) at 2 days postsurgery and GT. Bar = 50 µm. 
Data are expressed as mean ± SEM. *P < 0.05 versus sham/Ad.Null; 
†P < 0.05 versus MI/Ad.Null (n = 5 samples/group). Ad, adenovirus; 
hNGF, human nerve growth factor; MI, myocardial infarction; MMP, 
matrix metalloproteinase.
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supernatants of infarcted mice. Results show that MI induces a 
modest increase in SCF levels, with this effect being remarkably 
enhanced in infarcted mice receiving cardiac NGF-GT (Figure 3c).
NGF increases the abundance of c-kitpos cells in the 
BM
Next, we investigated the relationship between NGF-induced acti-
vation of the MMP9-SCF pathway and stem/PCs abundance and 
release. By immunohistochemical analyses, we found that NGF 
overexpression increased the number of total c-kitpos cells, and 
of c-kitpos/CD45low/neg and c-kitpos/CD45pos cells in the mouse BM 
at 3 days post-MI (Figure 4a–d). We additionally observed that 
NGF-GT differently impacts on the localization of c-kitpos cells 
within the BM endosteal and vascular niches: in fact, whereas the 
relative number of c-kitpos cells lining on the bone surface was not 
affected by NGF-GT (Figure 5a), the relative abundance of c-kitpos 
cells was found to be increased in proximity of the BM vascular 
niche (identified by staining for CD146) of Ad.hNGF-injected 
mice (Figure 5b,c). Moreover, the percentage of c-kitpos/Ki67pos 
proliferating cells in the BM was increased by NGF-GT at 3 days 
post-MI (Figure 5d,e). Similarly, flow cytometry analyses on total 
BM isolated at 3 days post-MI confirmed the increased percentage 
of c-kitpos cells in Ad.hNGF-injected mice (Figure 5f). To investi-
gate if the proliferation of c-kitpos cells is induced by NGF directly 
or through increased SCF,21,22 c-kitpos cells were isolated from the 
mouse BM using magnetic-activated cell sorting columns. Next, the 
expression of the NGF high-affinity receptor TrkA in the isolated 
c-kitpos cells was assessed by immunocytochemistry. In line with our 
previous findings on c-kitpos cells from the mouse infarcted heart,15 
we observed that murine BM c-kitpos cells do not express the TrkA 
receptor (data not shown), thus suggesting that, in mice, the NGF-
induced enhancement of c-kitpos cells is attributable to indirect 
mechanisms that are instead mediated through SCF.
NGF-dependent mobilization of BM-PCs and homing 
to the MI heart is dependent on MMP9 activation
We next sought to investigate the implication of MMP9 in 
the NGF-induced effects on BM-PCs (BM-derived PCs). 
Figure 3 Effects of NGF on MMP2 and SCF in the mouse bone marrow (BM) after MI and gene transfer. (a) Bar graph shows the expression 
of MMP2 in the mouse BM parenchyma at 1, 2, and 3 days following MI (or sham operation) and gene therapy. Data are expressed as number of 
MMP2pos cells/mm2 of BM parenchyma. (b) Representative microphotographs of MMP2pos BM cells (in brown) at 1 and 2 days postsurgery and gene 
therapy. Bar = 100 µm. (c) Bar graphs show the expression level of SCF (measured by ELISA) in the mouse BM supernatant at 2 and 3 days after 
surgery and cardiac gene therapy. Data are expressed as mean ± SEM. *P < 0.05 and **P < 0.01 versus sham/Ad.Null; †P < 0.05 and ††P < 0.01 versus 
MI/Ad.Null (n = 5 samples/group for MMP2 staining and 4 samples/group for ELISA assay). Ad, adenovirus; hNGF, human nerve growth factor; MI, 
myocardial infarction; MMP, matrix metalloproteinase; SCF, stem cell factor.
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Intramyocardial delivery of either Ad.hNGF or Ad.Null were 
performed in MMP9 knockout (KO) and C57BL/6 mice (control 
wild-type mice on same genetic background as MMP9 KO) after 
inducing MI or sham operation. Similarly to what previously 
observed in CD1 mice,15 cardiac flow cytometry analyses per-
formed in the C57BL/6 wild-type mice confirmed an increase 
of Linneg/c-kitpos cells at 3 days post-MI, with this effect being 
further incremented by NGF-GT (Figure 6a–e). The number of 
Linneg/c-kitpos cells was similar in the infarcted hearts of MMP9 
KO mice and wild-type controls. However, MMP9 deletion was 
associated with a reduction of the inductive effect of NGF on 
Linneg/c-kitpos cells (Figure 6a–e), thus suggesting that NGF elic-
its its effect on BM-PC mobilization and/or PC homing to the 
infarcted heart via a MMP9-dependent mechanism. This is in 
line with previous report showing NGF to increase MMP9, and 
MMP9 contributes to NGF effects in different cells.23,24 Similar 
to what observed in CD1 mice, the percentage of c-kitpos/Ki67pos 
proliferating cells in the BM of C57BL6/J mice was enhanced by 
Ad.hNGF after MI but remained unchanged in MMP9 KO mice 
(data not shown). Interestingly, the percentage of Linneg/c-kitpos 
cells in the PB at 3 days post-MI was significantly enhanced by 
Ad.hNGF in wild-type mice but it was blunted by MMP9 dele-
tion (Figure 6f).
BM origin of c-kitpos cells after NGF-GT in mice  
with MI
In order to investigate the BM origin of the linneg/c-kitpos cells 
enriched in the infarcted mouse heart by cardiac NGF-GT, we 
used a mouse model of BM transplantation. C57BL/6-Tg[CAG-
EGFP]1Osb/J, carrying an enhanced green fluorescent protein 
(eGFP), were used as donors and C57BL6/J as recipient mice 
(Figure 7a). Success of BM transplantation was confirmed by flow 
cytometry analysis of PB collected at 8 weeks after GFP-BM cells 
transplantation (Figure 7b–d). Fluorescent intensity showed that 
69 ± 6% of all nucleated cells expressed the fluorescent marker, 
indicating successful replacement of the BM cells population. 
Cardiac flow cytometry performed at 3 days post-MI and GT 
showed increased abundance of BM-derived Linneg/c-kitpos/GFPpos 
cells into the infarcted heart treated with Ad.hNGF (Figure 7e–k), 
thus providing evidence of the capacity of NGF to attract BM-PCs 
to the infarcted heart.
NGF is a chemoattractant for human BM- and  
PB-derived MNCs
Contrarily to mouse c-kitpos cells, human c-kitpos cells possess 
TrkA receptor for NGF and therefore they might use this receptor 
to directly respond to an NGF stimulus. As shown in Figure 8a–c, 
Figure 4 Effect of cardiac NGF gene therapy on c-kitpos progenitor cells in the mouse bone marrow (BM). (a) Immunofluorescence staining for 
c-kit (red fluorescence) and CD45 (green fluorescence) in the mouse BM at 3 days post-MI and gene therapy. White arrows indicate c-kitpos cells. Bar = 
25 µm. Bar graphs indicate the number of (b) c-kitpos cells, (c) c-kitpos/CD45low/neg cells, (d) and c-kitpos/CD45pos cells (all expressed as number of posi-
tive cells/105 total BM cells) at 3 days after surgery and gene transfer. Data are expressed as mean ± SEM. *P < 0.05 and **P < 0.01 versus sham/Ad.
Null; †P < 0.05 versus MI/Ad.Null. All analyses were performed at 3 days postsurgery (n = 5 mice/group). Ad, adenovirus; hNGF, human nerve growth 
factor; MI, myocardial infarction.
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flow cytometry confirmed the presence of Linneg/c-kitpos/TrkApos 
cells within the human BM-MNCs. In order to evaluate the poten-
tial effect of NGF on human BM-MNCs, cells were subjected to 
a Transwell migration assay using NGF as chemoattractant. As 
shown in Figure 8d, NGF attracted human BM-MNCs simi-
larly to what observed with SDF-1 (positive control) treatment. 
Furthermore, flow cytometry analyses showed that NGF migra-
tion enriched for CD34pos/c-kitpos and CD34pos/c-kitpos/TrkApos 
cells (calculated as ratio of migrated to nonmigrated cells), sug-
gesting that NGF was able to attract these BM-PC populations 
(Figure 8e,f, respectively). In addition, the NGF-induced BM-PC 
migration was repressed by the TrkA inhibitor K252a.
TrkA-expressing BM-derived CD34pos/c-kitpos cells are 
increased in the peripheral circulation of patients 
with acute MI
Flow cytometry analyses on clinical samples showed that the 
abundance of CD34pos/c-kitpos cells coexpressing the TrkA receptor 
was increased in the PB of acute MI patients (within 5 days from 
acute MI)25 in comparisons with healthy controls (Figure 8g). 
Figure 5 Effect of cardiac NGF gene therapy on c-kitpos cells localization in the mouse bone marrow (BM). Bar graphs shows (a) number of 
c-kitpos cells lining on the BM endosteal region and (b) number of c-kitpos cells in proximity to the vascular niche. (c) Representative microphotographs 
of c-kitpos cells (red fluorescence) in the proximity of the BM vascular niche (identified by staining for CD146, green fluorescence). c-kitpos cells close to 
the vascular niche are pointed by white arrows while c-kitpos cells that are distant from the vascular niche are indicated by yellow arrows. Bar = 25 µm. 
(d) Immunohistochemical staining for c-kit (red fluorescence) and the proliferative marker Ki67 (green fluorescence) in the BM showing increased 
proliferation of c-kitpos cells induced by Ad.hNGF at 3 days after MI and gene therapy (e); Bar = 25 µm. Nuclei are stained by 4′,6-diamidino-2-phe-
nylindole (blue fluorescence). (f) Quantification of Linneg/c-kitpos cells by flow cytometry in the BM of mice at 3 days post-MI and gene transfer. Data 
are expressed as mean ± SEM. *P < 0.05 and **P < 0.01 versus sham/Ad.Null; †P < 0.05 and ††P < 0.01 versus MI/Ad.Null. All analyses were performed 
at 3 days postoperation (n = 5 mice/group). Ad, adenovirus; hNGF, human nerve growth factor; MI, myocardial infarction.
Sham/Ad.Null
25
100
**
††
**
*
††
80
60
40
20
0
20
**
†
N
r o
f c
-k
itp
os
 
ce
lls
 in
th
e 
va
sc
ul
ar
 n
ic
he
%
 o
f c
-k
itp
os
 
Ki
67
po
s  
ce
lls
%
 o
f L
in
n
e
g /c
-K
itp
os
6
5
4
3
2
1
0
c-
ki
tpo
s  
ce
lls
/m
m
6
8
4
2
0
15
10
5
0
MI/Ad.Null
MI/Ad.hNGF
Sham/Ad.Null
MI/Ad.Null
MI/Ad.hNGF
a
b
d
e f
c
Molecular Therapy vol. 23 no. 12 dec. 2015 1859
Official journal of the American Society of Gene & Cell Therapy
NGF and Progenitor Cells Mobilization
Characteristics of acute MI patients and control subjects are 
shown in Supplementary Table S1.
DISCUSSION
Meta-analysis reports indicate that autologous transplantation of 
BM-MNCs produces modest improvement in LV function in acute 
MI patients.26 However, the uniformly null findings emerging from 
the most recent trials open new controversies in this already trou-
bled field of clinical research.26 Another experimental approach 
for stem/PCs–mediated therapy of MI consists of acute stem/PCs 
mobilization from the BM using G-CSF or equivalent chemokines. 
However, a recent systematic review of G-CSF clinical trials does 
not support this approach to produce substantial therapeutic ben-
efit in MI patients.27 Besides G-CSF, other chemokines and growth 
factors (such as vascular endothelial growth factor, erythropoie-
tin, fibroblast growth factor, and insulin-like growth factor) have 
been shown to induce BM-PCs mobilization and promote cardiac 
repair following MI. However, besides promising preclinical data, 
randomized, controlled clinical trials showed contrasting results 
and these factors necessitate of further investigation.28 Indeed, 
depending on the dose, as well as the timing of administration, 
chemokines and growth factors can either induce or have no effect 
on BM-PCs mobilization.28 Of note, another approach consisting 
of G-CSF–mediated mobilization of BM-PCs together with con-
comitant PC therapy showed conflicting results.29,30 In fact, despite 
the favorable effects of G-CSF therapy with concomitant intra-
coronary infusion of PCs on cardiac function and angiogenesis, 
aggravation of restenosis or recurrent MI was observed in several 
Figure 6 Involvement of MMP9 in the NGF-induced mobilization of bone marrow–derived progenitor cells. Identification and quantification 
of Linneg/c-kitpos cells by cardiac flow cytometry in MMP9 KO and WT (C57BL6/J) mice. (a) Forward and side scatter shows the total population (P2, 
in red) analyzed after LV digestion. For data analysis, counting beads (P1, green) were identified by their size. (b) Linneg cells (P3) were gated from 
the total population of extracted cells. (c) Negative control for c-kitpos cells (P4). Representative (d) dot plots and (e) bar graphs show the number of 
Linneg/c-kitpos cells/mg of LV tissue in MI hearts of WT mice (blue bars) and MMP9 KO mice (black bars) injected with Ad.hNGF. (f) Bar graphs show 
Linneg/c-kitpos cells mobilization in the peripheral blood (analyzed by flow cytometry). Data are expressed as mean ± SEM. *P < 0.05 and **P < 0.01 
versus WT sham/Ad.Null; †P < 0.05 and ††P < 0.01 versus WT MI/Ad.Null; ‡‡P < 0.01 versus WT MI/Ad.hNGF; §P < 0.05 versus MMP9 KO sham/Ad.Null. 
All analyses were performed at 3 days postoperation (n = 5 mice/group). Ad, adenovirus; hNGF, human nerve growth factor; KO, knockout; LV, left 
ventricle; MI, myocardial infarction; MMP, matrix metalloproteinase; WT, wild-type.
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MI patients.29,30 Nonetheless, it is likely that PC mobilizing fac-
tors (over)expressed (by local gene therapy) and released by the 
infarcted heart for a sufficient time frame which overlaps with the 
“therapeutic window” could continuously recruit BM-PCs to the 
myocardium, thus producing meaningful therapeutic results. We 
were the first to identify the strong therapeutic potential of local 
NGF-GT in a mouse MI model15 and we aim to embark in a trans-
lational pathway to meet the therapeutic needs of ischemic heart 
disease patients. Consequently, we are interested in elucidating 
the full range of mechanisms underpinning the beneficial effect 
of local NGF delivery. This study was designed to characterize the 
possible BM responses to cardiac NGF overexpression follow-
ing MI induction in mice. We have shown that MI per se leads 
to osteoclast activation. Moreover, cardiac NGF-GT expands the 
BM remodeling responses to MI and is conductive to increase of 
BM-PCs in the infarcted heart.
Mobilization of PCs from the BM is strictly regulated under 
either physiological conditions3,31 or stress situations5 (such as 
ischemia or inflammation), it is influenced by different cell types 
and requires many complex signals. There are three main steps 
involved in successful migration and engraftment of BM-PCs into 
the injured tissue: the PCs expansion and translocation from the 
endosteal niche to the vascular niche, their egress into the circu-
lation, and finally their recruitment into the target organ.12,32 In 
the present study, we demonstrate for the first time that NGF is 
involved in these three steps and in particular that Ad-mediated 
cardiac NGF overexpression induces mobilization of BM-PCs and 
their homing into the infarcted myocardium in mice.
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Besides the essential contribution in the regulation of bone 
reabsorption, osteoclasts have been recently shown to play a sig-
nificant role in the homeostasis and mobilization of BM-PCs.1 
Osteoclasts derive from the monocyte/macrophage cell lineage 
and their formation is mainly driven by M-CSF and RANKL.18,33 
Interestingly, a recent study by Hemingway et al. demonstrated 
that NGF, as well as other cytokines, is able to induce osteoclasts 
formation and activation independently of RANKL.34 In line with 
that, here we confirm the ability of NGF to induce the formation of 
TRAPpos osteoclasts (from BM-MNCs) in vitro and we addition-
ally show that terminally differentiated multinucleated osteoclasts 
possess the NGF receptor TrkA. Of note, higher doses of NGF 
(100 ng) produce lower effects on murine BM-MNCs undergo-
ing osteoclast differentiation as compared to lower doses (10 and 
50 ng). In this context, previous reports indicate that NGF dosage 
is crucial in determining the extent of its effects35,36 and we can 
speculate that high doses of NGF saturate its binding to its high-
affinity receptor TrkA and attenuate its effects. This finding might 
also explain the increased rate of active osteoclasts observed in 
our in vivo model of MI after NGF overexpression. In fact, it is 
known that several stress signals, including cardiac ischemia, 
induce and enhance osteoclasts activity32,37 (as observed here at 3 
days after MI and cardiac Ad.Null gene therapy). Importantly, we 
have found that cardiac Ad.hNGF gene therapy after MI induces a 
more rapid and sustained activation of osteoclasts in comparison 
to MI controls. In turn, osteoclasts activation triggers the secretion 
of cytokines, proteolytic enzymes (including MMP9), and mem-
brane-bound SCF.1 Herein, we demonstrate that NGF-induced 
osteoclasts activation is followed by release of active MMP9 in the 
mouse BM parenchyma. NGF is known to induce MMP9 expres-
sion.23,38,39 NGF-induced enhanced expression of MMP9 has been 
shown to promote corneal epithelial cells migration in vitro and 
in vivo.39 In turn, MMP9 plays an important role in BM cell migra-
tion. In fact, MMP9 cleaves the cell surface of the soluble c-kit 
ligand SCF and SCF contributes to the recruitment and mobili-
zation of hematopoietic stem/PCs.12,40 In the present study, using 
a KO mouse model, we demonstrate that MMP9 is essential for 
NGF-induced mobilization of BM-PCs into the circulation and 
PC homing to the infarcted heart. In fact, by flow cytometry, we 
found that the frequency of Linneg/c-kitpos cells in both the PB and 
the LV of MMP9 KO mice treated with Ad.hNGF was reduced and 
it was comparable to what observed in the PB and infarcted hearts 
of both wild-type and MMP9 KO mice treated with Ad.Null. Most 
notably, NGF gene therapy in infarcted hearts of GFP-BM chime-
ric mice confirmed the capacity of cardiac NGF overexpression 
to mobilize and attract BM-PCs to the infarcted heart. The pres-
ent study, together with our recent findings that NGF promotes 
cardiac repair after MI,15 advances the idea that the cardiopro-
tective effect of NGF might be partially mediated by its ability 
to recruit BM progenitors to the myocardium. Furthermore, we 
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Figure 7 BM transplantation studies. (a) Schematic representation of BM transplantation studies: GFPpos cells (in green) were isolated from the 
BM of GFPpos transgenic mice and subsequently transplanted into sublethally irradiated recipient C57BL/6 mice. After 8 weeks, mice underwent MI 
and cardiac gene therapy. (b–d) Efficacy of BM transplantation evaluated by flow cytometry for GFP on peripheral blood (PB) collected from mice 
at 6 weeks after sublethal irradiation and transplantation. (b) Forward and side scatter shows the total population analyzed (P2, in red). Counting 
beads (P1, in blue) were used to determine the absolute number of GFPpos cells. (c) Negative control for GFPpos cells (P3). GFPpos cells were gated 
from the total population. (d) Fluorescent intensity shows the percentage of all nucleated cells in the PB of chimeric mice that expressed GFP. (e–i) 
Identification and quantification of cardiac GFPpos/Linneg/c-kitpos cells by flow cytometry. Forward and side scatter (e) shows the total population 
analyzed (P2, in green) after digestion of the left ventricle (LV). Counting beads (P1, in red) were used to determine the absolute number of progeni-
tor cells per gram of LV. (f) Distribution of GFPpos cells (in P3) isolated from the LV of a transplanted recipient mouse. (g) Negative control for GFP, 
established using cells isolated from the LV of nontransplanted mice. (h) Lin-cells were gated from GFPpos cells (P4). (i) Negative control for c-kit. 
Representative (j) dot plots and (k) bar graphs show the number of GFPpos/Linneg/c-kitpos cells/mg of LV tissue after MI and cardiac Ad.hNGF treatment. 
Data are expressed as mean ± SEM. **P < 0.01 and *P < 0.05 versus Sham/Ad.Null; ††P < 0.01 versus MI/Ad.Null (n = 6 mice/group). Ad, adenovirus; 
BM, bone marrow; GFP, green fluorescent protein; hNGF, human nerve growth factor; MI, myocardial infarction
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have recently revealed that increase of SCF induced by NGF in the 
MI heart promotes the expansion of cardiac c-kitpos cells.15 Here, 
we additionally demonstrate that NGF, possibly through MMP9, 
leads to SCF increase in the mouse BM, followed by proliferation 
of c-kitpos PCs in the BM parenchyma.
However, our in vivo data suggest that NGF is not able to directly 
induce PC mobilization from the mouse BM (as mouse c-kitpos 
cells do not possess the NGF high-affinity receptor TrkA), where 
MMP9 and SCF appear to be essential. Conversely, TrkA is present 
on c-kitpos cells isolated from the human BM and it induces their 
migration in vitro, as supported by the fact that the TrkA inhibi-
tor K252a potently suppresses migration of CD34pos/c-kitpos and 
CD34pos/c-kitpos/TrkApos cells towards NGF. These results may have 
clinical relevance for the treatment of ischemic heart disease with 
therapies aimed at inducing BM-PC mobilization and suggest NGF 
as an important additional therapeutic factor that can contribute 
to cardiac repair using local and BM-mediated cellular responses. 
In this context, Ad-mediated NGF gene therapy could be consid-
ered as a potential therapeutic approach in the setting of ischemic 
heart diseases. To date, the majority of gene therapy clinical has 
been based on Ad vectors (http://www.wiley.co.uk/genmed/clini-
cal). Due to their high GT efficiency, viral vectors remain the most 
promising GT agents. In particular, Ad vectors represent one of the 
best viral vector candidate for human gene therapy approaches, as 
they have a high transduction efficiency, can be produced at high 
titer, and very rarely integrate into the host genome, thus reduc-
ing the risk of insertional mutagenesis.41 On the other side, their 
immunogenicity and transient expression may represent a major 
limitation for Ad-mediated gene therapy.42 Therefore, although 
their current limitations, Ad vectors represent one of the most effi-
cient tools for in vivo gene delivery and hold promise for clinical 
applications requiring a transient transgene expression.
In summary, our data suggest that NGF, through activation 
of osteoclasts and MMP9 and the release of SCF, stimulates the 
proliferation of c-kitpos PCs in the BM, thus facilitating PC mobili-
zation into the circulation and their homing to the infarcted heart. 
In this context, it is important to underline that NGF is a secreted 
factor and acts extracellularly on its receptor (TrkA), thus any cell 
type that possess the TrkA receptor can still benefit of its effect.
However, we cannot exclude other potential simultaneous 
mechanisms whereby NGF might act on BM-PCs, such as regu-
lating catecholamine release through activation of the sympa-
thetic nervous system43 or activating other key factors involved 
in BM-PC egress into the circulation (i.e., vascular endothe-
lial growth factor, SDF-1).9,16 Further investigation will clarify 
these mechanisms and their relative contributions to post-MI 
recovery.
MATERIALS AND METHODS
In vivo mouse studies. Mice were handled in accordance with the Guide 
for the Care and Use of Laboratory Animals prepared by the Institute 
of Laboratory Animal Resources and with the prior approval of the UK 
Home Office and the First Ethical Commission in Warsaw, Poland. Eight to 
ten-week-old CD1, C57BL/6 (both strains from Harlan, Huntingdon, UK), 
and MMP9 KO mice (in a C57BL/6 background originally obtained from 
Dr. Z. Werb, UCSF, San Francisco, CA) underwent MI induction, as previ-
ously described.15,19 Briefly, mice were anaesthetized (Avertin, 880 mmol/
Figure 8 In vitro migration of bone marrow (BM)- and peripheral blood (PB)-derived mononuclear cells (MNCs) towards NGF. (a–c) 
Identification by flow cytometry of c-kitpos/TrkApos cells in human BM-derived MNCs. (a) Forward and side scatter shows the total population analyzed 
(P1). (b) c-kitpos cells (P2) were gated from the total cells population and double-positive cells for c-kit and TrkA (c) are shown in P3. (d–f) Quantitative 
analysis of human BM-derived MNCs (obtained from noncardiovascular patients) after in vitro Transwell migration towards NGF shows migration of 
human MNCs (d) and enrichment for CD34pos/c-kitpos (e) and CD34pos/c-kitpos/TrkApos (f). The TrkA inhibitor K252a was used to repress NGF. (g) Bar 
graphs show the percentage of CD34pos/c-kitpos/TrkApos cells in the PB of either healthy subjects or patients with an acute MI (within 5 days following 
MI). BSA and SDF-1 have been used as negative and positive controls, respectively. Data are expressed as mean ± SEM. **P < 0.01 and *P < 0.05 versus 
BSA; ††P < 0.01 versus NGF; ‡P < 0.05 versus Healthy (n = 3 subjects/group for human BM samples and n = 11 subjects/group for human PB samples). 
aMI, acute myocardial infarction; BSA, bovine serum albumin; NGF, nerve growth factor; SDF, stromal cell–derived factor.
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kg, i.p.; Sigma Aldrich, Poole, UK), orally intubated, and artificially venti-
lated using a Minivent mouse ventilator (Harvard Apparatus, Kent, UK). 
The tidal volume was set at 8–9 µl/g and the respiratory rate was set at 140 
breaths per minute. Under a surgical microscope, an incision was made at 
the level of the left fifth intercostal space and MI was induced by perma-
nent ligation of the proximal left anterior descending coronary artery by 
using a 7.0 Mersilene suture (Ethicon, Somerville, NJ). Coronary occlusion 
was confirmed by pallor of the LV. GT was performed immediately after 
induction of MI. Under a surgical microscope, we entered the infarct zone 
using a 30 G needle bent at the right angle and injected the genetic material 
in three sites of the MI border zone. Mice were injected in the peri-infarct 
area (intramyocardially) with an adenoviral vector carrying human NGF 
(Ad.hNGF) at the dose of 108 plaque-forming unit (p.f.u.)/15 µl. Control MI 
mice were injected with an empty vector (Ad.Null). Sham-operated mice 
underwent the same procedure except left anterior descending coronary 
artery was circled with a 7-0 Mersilene but not occluded. Intramyocardial 
Ad.Null was also delivered to the LV of sham-operated mice. Surgical 
wounds were sutured and animals were allowed to recover.15,19
BM transplantation. For BM transplantation studies, transgenic mice 
expressing an eGFP cDNA under the control of a chicken β-actin pro-
moter and cytomegalovirus enhancer (C57BL/6-Tg[CAG-EGFP]1Osb/J; 
Jackson Laboratory, Bar Harbor, ME) were used (n = 2). Recipient mice 
(4- to 5-week-old C57BL/6 mice; n = 6 mice/group) received whole body 
irradiation (9.5 Gy), followed by injection of BM cells (1 × 106 eGFP-
expressing cells) into the tail vein. After 8 weeks, mice were subjected to 
MI induction and immediately injected with either Ad.hNGF or Ad.Null 
(108 p.f.u./15 µl) into the peri-infarct.15 Sham-operated mice received the 
same dose of Ad.Null.
Preparation of NGF adenoviral vector. As previously described,15,17 an 
adenoviral vector carrying human NGF-β (Ad.hNGF) was prepared by 
using the coding sequence for the NGF-β from p.NGF amplified (KOD 
proofreading DNA polymerase; Novagen, Darmstadt, Germany) using 
the following primers: 5′-GCTAGCGTAATGTCCATGTTGTTCTAC-3′ 
(NheI site) and 5′-GGATCCTCTCACAGCCT TCCT-3′ (BamHI site). 
A replication-deficient adenovirus was generated by site-specific Flippase-
mediated recombination of the cotransfected shuttle and genomic plas-
mids in 293 cells. Viral stocks were amplified, CsCl banded, and titrated.
Histology and immunohistochemistry on mouse bones. Femurs and tib-
iae were collected at 1, 2, 3, and 6 days after surgery. Bones were cleaned 
from muscles and connective tissues and kept for 24 hours in 10% buff-
ered formalin before being decalcified for 24 hours in 10% formic acid and 
embedded in paraffin. Bone sections (5 µm in thickness) were prepared 
into polylysine-coated slides and used for histological or immunohis-
tochemical analyses (n = 5 mice/group/time point). Bones were longi-
tudinally sectioned in order to comprise both epiphysis and diaphysis. 
Activated osteoclasts were detected by TRAP staining (acid phosphatase, 
Leukocyte kit; Sigma Aldrich). Sections were counterstained with hema-
toxylin. Osteoclasts were identified as TRAP-positive cells adjacent to bone 
surfaces.44 The number of osteoclasts was quantified (×20 magnification) 
and expressed as osteoclasts number per centimeter of bone perimeter. 
TRAP staining was evaluated in one bone section/mouse; 5.0 ± 1.7 cm of 
linear bone length per mouse was analyzed. Immunohistochemical stain-
ing for MMP2 and MMP9 were performed with polyclonal anti-MMP2 
(1:5,000) and anti-MMP9 (1:800) antibodies (Abcam, Cambridge, UK) 
and revealed by the REAL EnVision Detection System, Peroxidase/DAB 
(Dako, Stockport, UK). The number of MMP2- and MMP9-positive cells 
was analyzed (×20 magnification) and expressed as MMP-positive cells/
mm2. MMP2 and MMP9 were evaluated in two bone sections/mouse; 
12.1 ± 4.5 mm2 (for MMP2) and 12.5 ± 4.3 mm2 (for MMP9) of BM 
parenchyma per mouse was analyzed. Mouse c-kit (1:50; R&D Systems, 
Abingdon, UK) and CD45 antigens (1:10; Santa Cruz Biotechnology, Santa 
Cruz, CA) were used to identify hematopoietic PCs, Ki67 (1:500; Abcam) 
was used to verify the frequency of cycling c-kitpos cells, and CD146 (1:20; 
Abcam) to identify the BM vascular niche. Sections were visualized using 
a fluorescent microscope (×20 magnification). The number of c-kitpos, 
c-kitpos/CD45pos, and c-kitpos/CD45low/neg cells was expressed as positive 
cells/106 BM cells. C-kitpos cells in the BM vascular niche were expressed as 
number of positive cells for c-kit in proximity to the vascular niche (posi-
tive for CD146). Proliferating c-kit cells were expressed as percentage of 
double-positive cells for c-kit and Ki67. Appropriate nonimmune IgG were 
used to generate negative controls. For these staining, two bone sections/
mouse were employed and 12.0 ± 3.9 mm2 of BM parenchyma per mouse 
was analyzed; c-kitpos cells lining the BM endosteal region were assessed in 
3.8 ± 3.0 cm of linear bone length per mouse.
ELISA on BM supernatants. Femurs and tibiae (n = 4 mice/group/time 
point) were flushed in 0.5 ml of phosphate-buffered saline. After spinning, 
the BM supernatant was collected to perform ELISA assay for human and 
mouse NGF (PeproTech, London, UK) and mouse SCF (R&D Systems), 
following manufacturer’s instruction.
Immunocytochemistry on mouse BM c-kitpos cells. BM cells were isolated 
from femurs and tibiae of healthy mice (n = 3) by flushing with 2 ml of 
endothelial basal medium-2 (Lonza, Slough, UK). Cells were labeled with 
c-kit monoclonal antibody conjugated with magnetic beads (Miltenyi 
Biotec, Bisley, UK) and c-kitpos cells were selected by using magnetic-acti-
vated cell sorting separation columns (Miltenyi Biotec) according to the 
manufacture instructions. C-kitpos cells were cytospinned to glass slides 
(500 rpm for 5 minutes) and fixed with 4% paraformaldehyde. Double 
staining for c-kit (1:50; R&D Systems; secondary antibody: Alexa-568 
donkey anti-goat) and TrkA (1:50; Santa Cruz Biotechnology; secondary 
antibody: Alexa-488 goat anti-rabbit) was performed. Positive staining was 
visualized using a fluorescent microscope.
MNCs-osteoclasts differentiation. BM cells from healthy C57BL/6 mice 
(n = 3) were collected by flushing femurs and tibiae with 2 ml of alpha- 
Minimum Essential Media (Lonza). Cells were plated overnight in alpha-
Minimum Essential Media supplemented with 250 IU penicillin and 250 
µg streptomycin in order separate stromal cells (that adhere to the plate) 
from nonadherent MNCs. Nonadherent MNCs were then cultured (1 × 106 
cells/well in a 24-well plate) for 6 days in alpha-minimum essential medium 
supplemented with M-CSF (10 ng/ml; PeproTech) and RANKL (50 ng/ml; 
PeproTech) (both required for osteoclasts differentiation from MNCs). 
Next, immunohistochemistry for TrkA was performed to identify the pres-
ence of NGF high-affinity receptor on differentiated osteoclasts. Briefly, dif-
ferentiated cells were fixed with 4% paraformaldehyde, permeabilized with 
0.1% Triton-X, and stained with TrkA (1:50; Santa Cruz Biotechnology; 
secondary antibody: Alexa-488 goat anti-rabbit). Nuclei were identified 
by 4′,6-diamidino-2-phenylindole. In order to evaluate the NGF-induced 
formation of TRAPpos cells from MNCs, in a separate set of experiments, 
cultured MNCs (1 × 106 cells/well in a 24-well plate) were supplemented for 
6 days with M-CSF alone or in combination with NGF (10, 50, or 100 ng/
ml; Millipore, Watford, UK) before being submitted to TRAP staining. For 
these experiments, RANKL was omitted since NGF has been shown to 
induce RANKL-independent formation of TRAPpos cells.34
Flow cytometry analyses in mouse tissues. Evaluation of Linneg/c-kitpos 
cells was performed by flow cytometry in mouse PB, BM, and LV at 3 
days postoperation (n = 5 mice/group), as previously described.15 Mice 
were anesthetized (Avertin) and PB was collected by cardiac puncture. 
Next, hearts were harvested and blood was washed out with phosphate-
buffered saline. The LV was separated from right ventricle and septum, 
weighted, and minced. A “myocyte-depleted” cardiac cell population was 
prepared by enzymatic digestion of LV in 0.1% collagenase IV (30 min-
utes at 37 °C) and filtration through a 70-µm mesh. Total BM cells were 
flushed out from femurs and tibiae (additionally collected from the same 
mice) with 2 ml of Endothelial Basal Medium-2 (Lonza). The expression of 
1864 www.moleculartherapy.org vol. 23 no. 12 dec. 2015
Official journal of the American Society of Gene & Cell Therapy
NGF and Progenitor Cells Mobilization
c-kit (APC-Cy7 conjugated; BD Biosciences, Oxford, UK) was evaluated 
in isolated cells stained for anti-lineage markers antibodies (FITC conju-
gated; Caltag, Buckingham, UK). Evaluation of Linneg/c-kitpos/GFPpos cells 
was performed on mouse LV of chimeric mice at 3 days after surgery and 
GT. In order to assess the efficacy of BM transplantation, flow cytometry 
for GFP was also performed in PB collected by tail puncture at 8 weeks 
after GFP-BM cells transplantation. Unstained and single-stained controls 
were performed to define positivity. Fluorescence was analyzed in a Canto 
II flow cytometer using the Diva software (BD). Linneg/c-kitpos cells were 
expressed as percentage of total BM or PB cells. In order to determine the 
absolute number of PC populations per gram of heart, flow cytometry 
analyses were performed using fluorescent counting beads (Invitrogen, 
Paisley, UK). Following manufacturer instruction, 20,000 counting beads 
in 100 µl (same volume as sample) were added to the myocardial sample 
immediately before use. The final absolute count was determined by the 
formula: final absolute count = ((number of cells counted/total number of 
beads counted) × number of beads per ml)/mg of LV tissue.
Flow cytometry in human PB samples. Experimental procedures involv-
ing human subjects were performed in accordance with the Declaration 
of Helsinki and were approved by the responsible ethics committees. 
Research on clinical samples was performed in agreement with the Human 
Tissue Act (HTA). MNCs were isolated from PB (15 ml) obtained by vein 
puncture from a forearm vein of healthy volunteers (n = 11) and patients 
with acute MI (n = 11, provided by Dr. Marco Valgimigli, Cardiology 
Department, University of Ferrara, Ferrara, Italy) participating in a reg-
istered prospective clinical study (NCT01271309) at Ferrara University 
Hospital (Ferrara, Italy).25 All MI patients underwent percutaneous coro-
nary intervention immediately after admission to the hospital and prior to 
sampling for use in the current study.
Inclusion criteria. acute MI was defined as chest pain at rest lasting 
at least 20 minutes, transient or persistent ST segment ischemic ECG 
changes, and high levels of the cardiac necrosis markers creatine phospho-
kinase-muscle band and troponin. Optimal treatment included all drugs 
recommended by international guidelines except for statins, which were 
commenced only after collection of samples necessary to the study to avoid 
the confounding effect of these drugs on PC counting.
Exclusion criteria. Age below 18 years, anemia, hemodynamic instabil-
ity, systolic blood pressure <90 mmHg, alterations in hematopoiesis, can-
cer, and lack of consent to participate to the study.
MNCs were isolated by density centrifugation on Histopaque 1077 
(Sigma Aldrich, Milan, Italy) and stained for the hematopoietic PCs antigen 
CD34 (FITC conjugated; Miltenyi Biotec, Bologna, Italy) in combination 
with c-kit (APC conjugated; R&D Systems) and TrkA (PE conjugated; 
R&D Systems). CD34/c-kit/TrkA–positive cells were evaluated by flow 
cytometry and expressed as a percentage of total MNCs. Fluorescence was 
analyzed in a Canto II flow cytometer using the Diva software.
Transwell migration assay on human BM cells. Experimental proce-
dures involving human subjects were performed in accordance with the 
Declaration of Helsinki and were approved by the responsible ethics com-
mittees. Research on clinical samples was performed in agreement with 
the HTA.
Anonymized BM leftover samples were obtained from 
noncardiovascular patients (n = 3) undergoing hip replacement surgery 
at the Bristol Southmead Hospital (provided by Prof. Ashley Blom, 
Orthopaedic Surgery, Musculoskeletal Research Unit, University of 
Bristol, Bristol, UK). BM samples were collected as part of routine total hip 
replacement for osteoarthritis. All patients did consent and samples were 
provided anonymously to the research staff by the clinical staff. Briefly, the 
femoral neck was resected and a broach inserted into the proximal femur. 
The broach caused the displacement of marrow from the femoral canal 
and the marrow, commonly discarded, was collected and placed in sterile 
falcon tubes. The BM was then transferred into new falcon tubes containing 
phosphate-buffered saline with 5 mmol/l ethylenediaminetetraacetic acid. 
MNCs were isolated by density centrifugation on Histopaque 1077 (Sigma 
Aldrich). MNCs were resuspended in Endothelial Basal Medium-2 and 
seeded (6 × 106) on the upper part of six-transwell plate filters (pore size: 
3 µm). Endothelial Basal Medium-2 supplemented with NGF (100 ng/ml; 
Millipore) alone or in combination with the TrkA inhibitor K252a 
(100 nmol/l; Sigma Aldrich) was placed in the lower wells. SDF-1 (100 ng/ml; 
eBiosciences, Hatfield, UK) and bovine serum albumin (Sigma Aldrich) 
were used as positive and negative controls, respectively. After overnight 
incubation, migrated and nonmigrated cells were collected and stained for 
the hematopoietic PCs antigen CD34 (FITC conjugated; Miltenyi Biotec, 
Bisley, UK) in combination with c-kit (APC conjugated; R&D Systems) 
and TrkA (PE conjugated; R&D Systems). Total MNCs, as well as CD34/ 
c-kit– and CD34/c-kit/TrkA–positive cells were evaluated by flow cytometry 
and expressed as a ratio of migrated to nonmigrated cells. Fluorescence was 
analyzed in a Canto II flow cytometer using the Diva software.
Statistical analyses. Values are presented as mean ± SEM. Statistical sig-
nificance was evaluated through the use of an unpaired t-test for compari-
sons between two groups. For comparison among more than two groups, 
one-way analysis of variance was used, followed by Bonferroni post hoc 
test. Analyses were performed using the SigmaStat 3.1 software. A P value 
<0.05 was interpreted to denote statistical significance.
SUPPLEMENTARY MATERIAL
Table S1. Characteristics of acute MI patients and control subjects.
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